# Integra Lifesciences Holdings Corp (IART)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/integra-lifesciences-holdings-corp/ JSON: https://steadybase.io/company/integra-lifesciences-holdings-corp.json Checked Nov 10, 2026. Latest filing read: Oct 23, 2026.

## Company

- Legal name: INTEGRA LIFESCIENCES HOLDINGS CORP
- Ticker: IART (Nasdaq)
- SEC CIK: 0000917520
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: Princeton, NJ
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: integralife.com
- LinkedIn: https://www.linkedin.com/company/integra-lifesciences
- Next earnings date: Jan 14, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $1.6B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000011/0000917520-26-000011-index.html
- Operating income: -$493.4M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000011/0000917520-26-000011-index.html
- Net income: -$516.5M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000011/0000917520-26-000011-index.html
- SG&A: $699.7M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000011/0000917520-26-000011-index.html
- Employees: 4,427 as of , as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000011/iart-20251231.htm
- Shares outstanding: 77,800,976 as of Oct 22, 2026 (10-Q filed Oct 23, 2026). Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000077/0000917520-26-000077-index.html
- Auditor: Pricewaterhousecoopers LLP, Florham Park, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000011/iart-20251231.htm

## Business

Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives. We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/917520/000091752026000011/iart-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $1.6B | -$493.4M | -$516.5M | $699.7M |
| Dec 31, 2024 | $1.6B | $28.4M | -$6.9M | $717.0M |
| Dec 31, 2023 | $1.5B | $111.5M | $67.7M | $656.6M |
| Dec 31, 2022 | $1.6B | $238.9M | $180.6M | $616.3M |
| Dec 31, 2021 | $1.5B | $197.2M | $169.1M | $637.4M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/integra-lifesciences-holdings-corp.json

## Officers and directors

- Stuart Essig, Chairman and Chief Executive Officer. LinkedIn: https://linkedin.com/in/stuart-essig-8459174. Source: 8-K filed Oct 21, 2026, https://www.sec.gov/Archives/edgar/data/917520/000091752026000073/ex991-q32026earningsrelease.htm
- Mojdeh Poul, President & CEO. Source: Form 4 filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/917520/000174376026000003/0001743760-26-000003-index.htm
- Lea Daniels Knight, EVP & Chief Financial Officer. Source: Form 4 filed Jul 6, 2026, https://www.sec.gov/Archives/edgar/data/917520/000198374826000003/0001983748-26-000003-index.htm
- Lesha R. Shinn, CVP, Chief Legal Officer & Sec. LinkedIn: https://linkedin.com/in/lesha-shinn-89316122. Source: Form 3 filed Sep 28, 2026, https://www.sec.gov/Archives/edgar/data/917520/000215592226000002/0002155922-26-000002-index.htm
- Chantal Veillon-Berteloot, EVP & CHRO. Source: Form 4 filed Sep 4, 2026, https://www.sec.gov/Archives/edgar/data/917520/000199090526000004/0001990905-26-000004-index.htm
- Harvinder Singh, EVP & President, SS. LinkedIn: https://linkedin.com/in/harvinder-singh-533517. Source: Form 4 filed Jul 6, 2026, https://www.sec.gov/Archives/edgar/data/917520/000194978226000003/0001949782-26-000003-index.htm
- Robert T. Davis Jr., EVP & President, TR&DT. Source: Form 4 filed Jul 6, 2026, https://www.sec.gov/Archives/edgar/data/917520/000156360626000003/0001563606-26-000003-index.htm
- Michael J. McBreen, EVP & Chief Commercial Officer. Source: Form 4 filed Jun 3, 2026, https://www.sec.gov/Archives/edgar/data/917520/000181494326000003/0001814943-26-000003-index.htm
- Michael Damon Hutchinson, EVP, Chief Legal Officer & Sec. Source: Form 4 filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/917520/000160662626000004/0001606626-26-000004-index.htm
- Jeffrey Mosebrook, SVP, Fin & Princ Acct Officer. Source: Form 4 filed Jul 6, 2026, https://www.sec.gov/Archives/edgar/data/917520/000171968626000003/0001719686-26-000003-index.htm
- Andrea B. Caruso, CVP & CHRO. Source: Form 3 filed Oct 13, 2026, https://www.sec.gov/Archives/edgar/data/917520/000215979726000003/0002159797-26-000003-index.htm
- Barbara B. Hill, Board member (per proxy). Source: DEF 14A filed Apr 6, 2026, https://www.sec.gov/Archives/edgar/data/917520/000091752026000015/iart-20260406.htm
- Chantal Veillon, Named in proxy. LinkedIn: https://linkedin.com/in/chantalveillon. Source: DEF 14A filed Apr 6, 2026, https://www.sec.gov/Archives/edgar/data/917520/000091752026000015/iart-20260406.htm
- Christian S. Schade, Board member (per proxy). Source: DEF 14A filed Apr 6, 2026, https://www.sec.gov/Archives/edgar/data/917520/000091752026000015/iart-20260406.htm
- Jeffrey A. Graves, Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 6, 2026, https://www.sec.gov/Archives/edgar/data/917520/000091752026000015/iart-20260406.htm
- Keith Bradley, Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 6, 2026, https://www.sec.gov/Archives/edgar/data/917520/000091752026000015/iart-20260406.htm
- Lea Knight, Named in proxy. LinkedIn: https://www.linkedin.com/in/leadanielsknight. Source: DEF 14A filed Apr 6, 2026, https://www.sec.gov/Archives/edgar/data/917520/000091752026000015/iart-20260406.htm
- Michael Hutchinson, Named in proxy. Source: DEF 14A filed Apr 6, 2026, https://www.sec.gov/Archives/edgar/data/917520/000091752026000015/iart-20260406.htm
- Michael McBreen, Named in proxy. Source: DEF 14A filed Apr 6, 2026, https://www.sec.gov/Archives/edgar/data/917520/000091752026000015/iart-20260406.htm
- Stuart M. Essig, Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 6, 2026, https://www.sec.gov/Archives/edgar/data/917520/000091752026000015/iart-20260406.htm

## Recent 8-K events

- Oct 21, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000073/iart-20261021.htm
- Oct 19, 2026: Item 1.01, Entry into a material definitive agreement; Item 1.02, Termination of a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/917520/000119312526425271/d142199d8k.htm
- Oct 9, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/917520/000119312526419228/d151933d8k.htm
- Oct 2, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000067/iart-20261002.htm
- Sep 8, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000061/iart-20260908.htm
- Jul 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000055/iart-20260729.htm
- May 8, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000044/iart-20260507.htm
- May 5, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000034/iart-20260430.htm
- May 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000033/iart-20260505.htm
- Apr 15, 2026: Item 1.01, Entry into a material definitive agreement. Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000019/iart-20260410.htm

## Insider trades (Form 4)

- Nov 5, 2025: Jeffrey A. Graves (Director) bought 9,000 shares, about $102,150. Source: https://www.sec.gov/Archives/edgar/data/917520/000125103625000006/0001251036-25-000006-index.htm

## What management said

- "Our third quarter performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7 million impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing" Stuart Essig, Chairman and Chief Executive Officer (8-K filed Oct 21, 2026). Source: https://www.sec.gov/Archives/edgar/data/917520/000091752026000073/ex991-q32026earningsrelease.htm

## Latest filings

- 8-K filed Oct 21, 2026: https://www.sec.gov/Archives/edgar/data/917520/000091752026000073/iart-20261021.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/917520/000091752026000011/iart-20251231.htm
- 10-Q filed Oct 23, 2026: https://www.sec.gov/Archives/edgar/data/917520/000091752026000077/iart-20260930.htm
- DEF 14A filed Apr 6, 2026: https://www.sec.gov/Archives/edgar/data/917520/000091752026000015/iart-20260406.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/